Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/375 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME02640048
PMID: | 2640048
LR: | 20061115
CED: | 19900823
DCO: | 19900823
Autoren: | Dragani L; Formica LM; Pascale AM; Cicchitti G; Giamberardino MA
Titel: | Effetti dell'associazione eparina-glicuronilglucosaminoglicano per uso topico sulle modificazioni algosensitive e trofiche dei tessuti periarticolari in corso di gonartrosi. Effect of a combination of heparin-glucuronylglucosaminoglycan for topical use in modification of pain in osteoarthritis of the knee
Quelle: | Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue européenne pour les sciences médicales et pharmacologiques; VOL: 11 (3); p. 271-5 /198906/
PM: | Print
SU: | IM
Sprache: | Italian
CY: | ITALY
JID: | 8100897
ISSN: | 0392-291X
CO: | RESFDJ
DT: | English Abstract; Journal Article
Schlagwörter
CT: | ADMINISTRATION, TOPICAL; AGED; DRUG COMBINATIONS; FEMALE; GLYCOSAMINOGLYCANS/administration & dosage; GLYCOSAMINOGLYCANS/*therapeutic use; HEPARIN/administration & dosage; HEPARIN/*therapeutic use; HUMANS; KNEE; MALE; MIDDLE AGED; OSTEOARTHRITIS/*drug therapy; OSTEOARTHRITIS/physiopathology
CTG: | APPLIKATION, LOKALE; ALTE MENSCHEN; ARZNEIMITTELKOMBINATIONSPRÄPARATE; WEIBLICH; GLYCOSAMINO-GLYCANE/Verabreichung & Dosierung; GLYCOSAMINO-GLYCANE/*therapeutische Anwendung; HEPARIN/Verabreichung & Dosierung; HEPARIN/*therapeutische Anwendung; MENSCH; KNIE; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE/*Arzneimitteltherapie; OSTEOARTHROSE/Pathophysiologie
TE: | Drug Combinations; Glycosaminoglycans; glucuronyl glucosamine glycan sulfate/58915-48-3; Heparin/9005-49-6
CR: | 58915-48-3; 9005-49-6
AB: | The aim of the study was to evaluate the therapeutic effects of a Heparin-Glucuronilglucosaminoglycane association for external use in patients affected with painful osteoarthritis of the knee. The cutaneous pain threshold and subcutaneous tissue thickness at periarticular level were chosen as parameters for evaluation. In a previous experimental study, they proved to be reliable indexes of pain-related alterations of sensitivity and trophism. These parameters were measured in basal conditions and after 10, 20 and 30 days respectively of therapy consisting in 3 daily administrations of the drug. The measurements were also repeated 30 days after the interruption of the treatment. The cutaneous pain threshold and the subcutaneous tissure thickness underwent an increase and a decrease respectively in comparison with basal values in all the determinations performed. These increases and decreases were statistically significant throughout the whole period of treatment and remained significant even after the interruption of the drug administration (significant levels between p less than 0.04 and p less than 0.001). The possible mechanisms of such effects were examined, according to the pharmacological characteristics of the drug and the pathophysiology of pain and inflammation.

» Volltext »
» Fenster schließen »